Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

NCT02630693

Last updated date
Study Location
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Premenopausal and postmenopausal women 18 years of age or older.

- Histologically confirmed adenocarcinoma of the breast, with ER positive and HER2 negative status based on local testing on most recent pathological tumour specimen.

- Patients must satisfy the following criteria for prior therapy:

- Progressed during treatment or within 12 months of completion of adjuvant endocrine therapy or

- Progressed during prior endocrine therapy for advanced/metastatic disease. Note: 'Progressed during endocrine therapy' means that the patient progressed while on or within 1 month after discontinuation of endocrine therapy.

- One line of chemotherapy for advanced/metastatic disease (regardless of prior adjuvant chemotherapy use) is allowed in addition to endocrine therapy.

- Patients must have evidence of disease to be eligible for the study, but measurable disease is not mandatory.

- For those patient with measureable disease who will be included in the response assessment, the following criteria must apply:

- X-ray ≥ 20 mm

- Spiral CT scan or physical exam ≥ 10 mm (lymph nodes must be ≥ 15 mm in the short axis)

- Conventional CT scan, MRI ≥ 20 mm

- Measurable lesions must be outside a previous radiotherapy field if they are the sole site of disease, unless disease progression has been documented.

Tumor lesions previously irradiated or subjected to other loco regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented.

- Eastern Cooperative Oncology Group (ECOG) 0-2.

- Adequate organ and bone marrow function as defined by:

- ANC ≥ 1,500/mm3 (1.5 x 109/L)

- Platelets ≥ 100,000/mm3 (100 x 109/L)

- Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥60 ml/min as calculated using the method standard for the institution;

- Total serum bilirubin ≤ 1.5 x ULN (<3 ULN if Gilbert's disease).

- Patient must agree to provide tumour tissue from the most recent pathological tumour specimen.

- Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French

- Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate

- Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits placed on patients being considered for this trial.

- In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working days of patient randomization.

- Women of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with advanced, symptomatic, visceral spread that are at risk of life
threatening complication in the short term.


- Patients with symptomatic CNS involvement, meningeal or parenchymal, that is
uncontrolled or requires steroids.


- Prior treatment with any CDK 4/6 inhibitor.


- Prior treatment with mTOR inhibitors.


- Active second malignancy, regardless of ongoing treatment.


- Any concurrent medical condition that in the opinion of the investigator would
interfere with the safe administration of the study drug and participation in the
study.


- Participation in a prior anti-cancer investigational study within 30 days prior to
enrollment.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast CancerNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT03573648
  1. Washington, District of Columbia
  2. Baltimore, Maryland
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Breast CancerNeoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
NCT03819010
  1. Badalona, Barcelona
  2. Madrid,
  3. Valencia,
  4. Oporto,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Official Title  ICMJE Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
Brief Summary The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing regimen of 125 mg daily for 21 days out of a 28 day cycle in combination with endocrine therapy.
Detailed Description The standard or usual treatment of this type of breast cancer is endocrine therapy. Palbociclib is a new type of drug for breast cancer. Laboratory tests as well as studies in animals and people show that it may help slow the growth of breast cancer. The most widely tested regimen of Palbociclib for patients with metastatic/advanced breast cancer is 125 mg every day for 21 days out of a 28 day cycle in combination with standard endocrine (hormone) therapy. This study explores if administering a lower dose of palbociclib - 100 mg given every day of a 28 day cycle in combination with standard endocrine (hormone) therapy - may result in more tumour shrinkage and be better tolerated.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: Palbociclib 100mg
    100mg PO daily
  • Drug: Palbociclib 125mg
    125mg PO daily 3 weeks out of 4
  • Drug: Fulvestrant or Tamoxifen or Aromatase Inhibitor
    given at the standard doses/schedules
Study Arms  ICMJE
  • Active Comparator: Palbociclib (100mg)
    Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
    Interventions:
    • Drug: Palbociclib 100mg
    • Drug: Fulvestrant or Tamoxifen or Aromatase Inhibitor
  • Active Comparator: Palbociclib (125mg)
    Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
    Interventions:
    • Drug: Palbociclib 125mg
    • Drug: Fulvestrant or Tamoxifen or Aromatase Inhibitor
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 11, 2015)
180
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE November 16, 2018
Actual Primary Completion Date August 15, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Premenopausal and postmenopausal women 18 years of age or older.
  • Histologically confirmed adenocarcinoma of the breast, with ER positive and HER2 negative status based on local testing on most recent pathological tumour specimen.
  • Patients must satisfy the following criteria for prior therapy:

    • Progressed during treatment or within 12 months of completion of adjuvant endocrine therapy or
    • Progressed during prior endocrine therapy for advanced/metastatic disease. Note: 'Progressed during endocrine therapy' means that the patient progressed while on or within 1 month after discontinuation of endocrine therapy.
  • One line of chemotherapy for advanced/metastatic disease (regardless of prior adjuvant chemotherapy use) is allowed in addition to endocrine therapy.
  • Patients must have evidence of disease to be eligible for the study, but measurable disease is not mandatory.
  • For those patient with measureable disease who will be included in the response assessment, the following criteria must apply:

    • X-ray ? 20 mm
    • Spiral CT scan or physical exam ? 10 mm (lymph nodes must be ? 15 mm in the short axis)
    • Conventional CT scan, MRI ? 20 mm
    • Measurable lesions must be outside a previous radiotherapy field if they are the sole site of disease, unless disease progression has been documented.

Tumor lesions previously irradiated or subjected to other loco regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented.

  • Eastern Cooperative Oncology Group (ECOG) 0-2.
  • Adequate organ and bone marrow function as defined by:

    • ANC ? 1,500/mm3 (1.5 x 109/L)
    • Platelets ? 100,000/mm3 (100 x 109/L)
    • Serum creatinine ? 1.5 x ULN or estimated creatinine clearance ?60 ml/min as calculated using the method standard for the institution;
    • Total serum bilirubin ? 1.5 x ULN (<3 ULN if Gilbert's disease).
  • Patient must agree to provide tumour tissue from the most recent pathological tumour specimen.
  • Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
  • Patients must be accessible for treatment and follow up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits placed on patients being considered for this trial.
  • In accordance with NCIC CTG policy, protocol treatment is to begin within 2 working days of patient randomization.
  • Women of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion Criteria:

  • Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term.
  • Patients with symptomatic CNS involvement, meningeal or parenchymal, that is uncontrolled or requires steroids.
  • Prior treatment with any CDK 4/6 inhibitor.
  • Prior treatment with mTOR inhibitors.
  • Active second malignancy, regardless of ongoing treatment.
  • Any concurrent medical condition that in the opinion of the investigator would interfere with the safe administration of the study drug and participation in the study.
  • Participation in a prior anti-cancer investigational study within 30 days prior to enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02630693
Other Study ID Numbers  ICMJE MA38
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Canadian Cancer Trials Group
Study Sponsor  ICMJE Canadian Cancer Trials Group
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Study Chair:Anil A. JoyCross Cancer Institute, Edmonton Alberta Canada
PRS Account Canadian Cancer Trials Group
Verification Date March 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP